
Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target
Author(s) -
Athanasios Skarmoutsos,
Ioannis Skarmoutsos,
Ioannis Katafigiotis,
Elisavet Tataki,
Athina Giagini,
Christos Alamanis,
Ioannis Anastasiou,
Anastasios Angelou,
Mordechai Duvdevani,
Nikolaos M. Sitaras,
Constantinos Constantinides
Publication year - 2018
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1159/000447225
Subject(s) - medicine , prostate cancer , urine , receiver operating characteristic , biomarker , prostate specific antigen , prostate biopsy , platelet derived growth factor receptor , prostate , urology , pca3 , cancer , growth factor , pathology , biochemistry , chemistry , receptor
Although the prostate specific antigen revolutionized the diagnosis of prostate cancer (PCa), it has its limitations. We prospectively examined the potential use of the platelet-derived growth factor-BB (PDGF-BB) as a urine biomarker for the early diagnosis of PCa.